Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold

May 2, 2022 0

A lot is happening while the Stock Market is tanking and is finally being considered a …

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

April 27, 2022 0

Amgen Repatha Studies Repatha is the Longest Studied PCSK9i Amgen (AMGN) announced top-line results from two …

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

April 26, 2022 0

Gilead Sciences Receives sNDA from the FDA for Remdesivir for Pediatric Patients with COVID-19 Gilead Sciences …

Interesting News from PTC Therapeutics and Arcturus Therapeutics Holdings

April 20, 2022 0

Arcturus Therapeutics Holdings News Arcturus Therapeutics Holdings (ARCT) shared topline data from an ongoing Phase 1/2/3 …

Gilead Sciences: The FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies. See Also: BioNTech

April 13, 2022 0

FDA Lifts Partial Clinical Hold on Gilead Sciences Studies of Magrolimab On April 12, 2022, Gilead …

What’s Going on with the Clinical-Stage Biotech Firms. See Also: Promising News From Evotec SE

April 9, 2022 0

The Clinical Stage Biotech Firms We have reasons to believe that some clinical-stage biotechnology firms, …

Promising Agreement Between Jazz Pharmaceuticals and Werewolf Therapeutics

April 8, 2022 0

Jazz Pharmaceuticals and Werewolf Therapeutics Agreement Jazz Pharmaceuticals (JAZZ) and Werewolf Therapeutics (HOWL)

Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little or No Adverse Effects

April 5, 2022 0

Sunshine Biopharma mRNA Therapeutics Effective at Destroying Cancer Cells Sunshine Biopharma, Inc. (SBFM) – a pharmaceutical …

Gilead Sciences: The FDA Approved Yescarta® – The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

April 4, 2022 0

Gilead Sciences' Product Yescarta Kite - a Gilead Sciences (GILD) Company, announced the U.S. FDA has approved …

Reata Pharmaceuticals Completed Rolling NDA Submission of Omaveloxolone for Friedreich’s Ataxia

April 1, 2022 0

Reata Pharmaceuticals Completed Rolling NDA Submission for Omaveloxolone for Friedreich’s Ataxia Reata Pharmaceuticals (RETA) announced the …

News From Vertex and Cassava: Two Prohost Portfolio Selected Biotech Firms

March 31, 2022 0

Vertex Pharmaceuticals Statistically Significant Results From Vertex VX-548 for Acute Pain Vertex Pharmaceuticals (VRTX) announced positive …

Our Most Pressing Need. See Also: Important, Recent News from Incyte & Eli Lilly and Halozyme

March 29, 2022 0

Our Most Pressing Need Our current, most pressing need is news that makes sense. Stock Market …

Comprehensive Prohost Letter #449 – Reality

March 27, 2022 0

Comprehensive Prohost Letter Issues Reality The Best of words in informative texts are the smallest in …

What Happened Over the Past Two Days and Biotech

March 10, 2022 0

Some Gains in Biotech Stocks During the War in Europe On Tuesday, Mar 8,2022 the United …

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision

March 4, 2022 0

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision – In May 2012, the …

These Dangerous World Circumstances and the Prohost Portfolio

March 4, 2022 0

The circumstances that we find the world in today are abnormal. They are extremely intense and …

What Happens to Intellia When the U.S. Patent and Trademark Office Changes Previous Patent Decisions?

March 1, 2022 0

Intellia Therapeutics Loses Technology Patent and Suffers a Selloff A selloff of Intellia Therapeutics (NTLA) stock …

Our Plan as the Stock Market Continues to Plummet

February 17, 2022 2

The Stock Market Continues to Plummet Indeed, the Stock Market continues to decline, losing investors' profits. …

Karyopharm Therapeutics Getting a Boost in the Midst of a Chaotic Market

February 14, 2022 0

We do not dare invest in the stock market at a time when almost all the …

Who Forgot About Enanta Pharmaceuticals?

February 11, 2022 0

Enanta Pharmaceuticals Expectations Expecting Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

Interesting News from PTC Therapeutics and Arcturus Therapeutics Holdings

Gilead Sciences: The FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies. See Also: BioNTech

What’s Going on with the Clinical-Stage Biotech Firms. See Also: Promising News From Evotec SE

Promising Agreement Between Jazz Pharmaceuticals and Werewolf Therapeutics

Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little or No Adverse Effects

Gilead Sciences: The FDA Approved Yescarta® – The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

Reata Pharmaceuticals Completed Rolling NDA Submission of Omaveloxolone for Friedreich’s Ataxia

News From Vertex and Cassava: Two Prohost Portfolio Selected Biotech Firms

Our Most Pressing Need. See Also: Important, Recent News from Incyte & Eli Lilly and Halozyme

Comprehensive Prohost Letter #449 – Reality

What Happened Over the Past Two Days and Biotech

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision

These Dangerous World Circumstances and the Prohost Portfolio

What Happens to Intellia When the U.S. Patent and Trademark Office Changes Previous Patent Decisions?

Our Plan as the Stock Market Continues to Plummet

Karyopharm Therapeutics Getting a Boost in the Midst of a Chaotic Market

Who Forgot About Enanta Pharmaceuticals?